Search Results: PARP inhibitor

• For Researchers

PARP inhibitors: Halting cancer by halting DNA repair

How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors. How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors.

24 September 2020

• Health & Medicine

Hitting the self-destruct switch – standing up to womb cancer with PARP inhibitors

We take a look at what a new class of drugs called PARP inhibitors are doing to fight womb cancer. We take a look at what a new class of drugs called PARP inhibitors are doing to fight womb cancer.

23 July 2015

• Health & Medicine
• Science & Technology

News digest - lung stats, political action, PARP inhibitors and more

Here's our weekly round-up of the week's cancer research news Here's our weekly round-up of the week's cancer research news

25 October 2014

• Science & Technology
• Health & Medicine

Coming ever closer – first PARP inhibitor licensed in Europe

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

24 October 2014

• Science & Technology
• Health & Medicine

Widening the net for PARP inhibitors

12 July 2011

• Health & Medicine
• Science & Technology

NCRI Cancer Conference 2009 – Bigger benefits from PARP inhibitors

9 October 2009

• Science & Technology

PARG inhibitors: tipping the scales with a new experimental drug

Our scientists are developing a new experimental drug to target how cancer cells repair their DNA, and upset cancer's balance. Our scientists are developing a new experimental drug to target how cancer cells repair their DNA, and upset cancer's balance.

16 March 2017

• Health & Medicine

Better together: improving brain tumour treatment

We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective. We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

13 February 2023

• For Researchers

Rucaparib: targeting DNA repair and a patient's perspective

Our scientists have been at the forefront of PARP inhibitor research and development. Here we share the story of rucaparib. Our scientists have been at the forefront of PARP inhibitor research and development. Here we share the story of rucaparib.

21 July 2017

• Health & Medicine

Blocking key cell component could make 'smart drugs' effective for many cancer patients

Cancer Research UK scientists at Newcastle University and researchers based at Harvard University have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors. The research is published in Nature Medicine today. Cancer Research UK scientists at Newcastle University and researchers based at Harvard University have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors. The research is published in Nature Medicine today.

26 June 2011

• Health & Medicine

Test selects the 60 per cent of women with inherited ovarian cancer who could benefit from 'smart' drug

Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool. Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool.

8 November 2010